

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
September 23, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

September 23, 2009

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g-32(b):82-\_\_\_\_\_

RESEARCH UPDATE

UPDATE ON TIMELINE FOR FORMAL FEEDBACK ON LIRAGLUTIDE FROM THE FDA

Novo Nordisk today announced that formal feedback from the United States Food  
and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1  
analogue, has been deferred until the fourth quarter of 2009. Novo Nordisk  
continues the constructive dialogue with the FDA regarding the regulatory

## Edgar Filing: NOVO NORDISK A S - Form 6-K

process for liraglutide.

Novo Nordisk expects to provide an update on the regulatory process for liraglutide in connection with the announcement of the financial results for the first nine months of 2009, on 29 October 2009, if formal feedback is not received before then.

This update on the timeline for formal feedback on liraglutide from the FDA does not change Novo Nordisk's expectations for the company's financial results for 2009, which were provided on 6 August in connection with the release of the financial results for the first six months of 2009.

### ABOUT LIRAGLUTIDE

Liraglutide is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when glucose levels become too high and by inhibiting appetite. On 23 May 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration (FDA) in the US for the approval of liraglutide for the treatment of people with type 2 diabetes. In Europe, Novo Nordisk received marketing authorization for liraglutide under the brand name Victoza(R) on 3 July and Victoza(R) has subsequently been launched. A New Drug Application was also submitted for approval in Japan on 14 July 2008.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

Further information:

#### Media:

Mike Rulis  
Tel: (+45) 4442 3573  
[mike@novonordisk.com](mailto:mike@novonordisk.com)

#### Investors:

Mads Veggerby Lausten  
Tel: (+45) 4443 7919  
[mlau@novonordisk.com](mailto:mlau@novonordisk.com)

Kasper Roseeuw Poulsen  
Tel: (+45) 4442 4471  
[krop@novonordisk.com](mailto:krop@novonordisk.com)

#### In North America:

Sean Clements  
Tel: (+1) 609 514 8316  
[secl@novonordisk.com](mailto:secl@novonordisk.com)

#### In North America:

Hans Rommer  
Tel: (+1) 609 919 7937  
[hrrmm@novonordisk.com](mailto:hrrmm@novonordisk.com)

Company Announcement no 56 / 2009

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: September 23, 2009

NOVO NORDISK A/S

Edgar Filing: NOVO NORDISK A S - Form 6-K

-----  
Lars Rebien Sorensen,  
President and Chief Executive Officer